News headlines Vertex Pharmaceuticals (VRTX) is gaining traction with strong kidney data and regulatory advancements for its drug povetacicept. The company has raised its revenue guidance for 2025, ...

EHA: Vertex, CRISPR build case for gene-editing drug A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Abstract: An efficient implicit representation of an n-vertex graph G in a family $\mathcal{F}$ of graphs assigns to each vertex of G a binary code of length O(log n) so that the adjacency between ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.